Delcath Systems, INC Form 4 insider transactions

Director John Richard Sylvester was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

Director Bridget A. Martell was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

Director Elizabeth Czerepak was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

Director Steven A.J. Salamon was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

Director Aharon Gil was granted 22,500 stock options in Delcath Systems, Inc. as part of the company's equity incentive plan.

DELCATH SYSTEMS, INC. CFO Sandra Pennell acquired 5,533 shares of common stock at $9.04 per share.

Delcath Systems, Inc. granted General Counsel David L. Hoffman 56,500 stock options and 28,250 restricted stock units.

Delcath Systems, Inc. has granted stock options and restricted stock units to Kevin Muir, General Manager of Interventional Oncology, as part of its equity incentive plan.

Delcath Systems' Chief Financial Officer, Sandra Pennell, received a grant of 56,500 stock options and 28,250 restricted stock units.

Delcath Systems' Chief Medical Officer, Vojo Vukovic, received significant equity awards, including stock options and restricted stock units, tied to future vesting schedules.

Delcath Systems' Chief Operating Officer, Martha S. Rook, received stock options and restricted stock units as part of her compensation.

Delcath Systems CEO Gerard J. Michel received grants of 195,000 stock options and 97,500 restricted stock units, vesting over several years.

DELCATH Systems Director John Richard Sylvester acquired 4,386 shares of common stock at $8.89 per share under a pre-arranged 10b5-1 trading plan.

DELCATH SYSTEMS, INC. CEO Gerard J. Michel acquired 11,500 shares of common stock at $8.526 per share through a pre-arranged trading plan.

Delcath Systems, Inc.'s Chief Medical Officer, Vojo Vukovic, exercised stock options to acquire 42,000 shares of common stock at $4.78 per share, increasing his direct beneficial ownership.

Director John Richard Sylvester acquired stock options in Delcath Systems, Inc. on May 15, 2025.

Director Steven Salamon acquired stock options in Delcath Systems, Inc. on May 15, 2025.

Elizabeth Czerepak, a director of Delcath Systems, Inc., reports the acquisition of stock options.

Director Aharon Gil acquired stock options in Delcath Systems, Inc. on May 15, 2025.

Bridget A. Martell, a director of Delcath Systems, Inc., was granted stock options to purchase 22,500 shares of common stock on May 15, 2025.

Director Aharon Gil reports the acquisition of 400,000 common shares of Delcath Systems through the exercise of warrants.

Director Steven Salamon reports the acquisition of 400,000 common shares of Delcath Systems through the exercise of warrants by Rosalind Opportunities Fund I L.P.

Rosalind Advisors, along with related individuals, reports acquisition of 400,000 common shares of Delcath Systems through warrant exercise, impacting their beneficial ownership.

David L. Hoffman, General Counsel, CCO & Secretary of Delcath Systems, Inc., reports acquisition of stock options.

Sandra Pennell, CFO of Delcath Systems, Inc., reports the acquisition of stock options.

Kevin Muir, GM of Interventional Oncology at Delcath Systems, acquired 113,000 stock options on February 7, 2025.

Martha S. Rook, Chief Operating Officer of Delcath Systems, Inc., reports the acquisition of stock options.

Vojo Vukovic, Chief Medical Officer of Delcath Systems, Inc., reports the acquisition of stock options exercisable for 113,000 shares of common stock.

Delcath Systems CEO Gerard Michel was granted stock options to purchase 390,000 shares of common stock on February 7, 2025.

Delcath Systems director Steven Salamon converted warrants into common shares and pre-funded warrants, increasing his indirect holdings.